Sponsor:
UCLA
Code:
NCT03749187
Conditions
Glioblastoma
IDH1 Gene Mutation
IDH2 Gene Mutation
Low Grade Glioma
Malignant Glioma
Eligibility Criteria
Sex: All
Age: 13 - 25
Healthy Volunteers: Not accepted
Interventions
PARP Inhibitor BGB-290
Temozolomide
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2025-04-04.